Skip to main content
SpringerLink
Log in

Management of Metastatic Colorectal Carcinoma in Older Adults: Balancing Risks and Benefits of Novel Therapies

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

The prevalence of older patients with metastatic colorectal cancer (mCRC) will continue to increase with our aging population. Treatment of mCRC has changed significantly in the last few decades as we have learned how to personalize the treatment of mCRC to the biology of the tumor, utilizing new treatment approaches. With an ever-changing treatment paradigm, managing the population of older adults becomes paramount. This review highlights the pivotal clinical trials that defined the use of systemic therapy, immunotherapy and targeted therapies for mCRC, and how those are applied to the older patient population. In addition, we outline the tools for an in-depth assessment of an older adult in regards to treatment planning and management of therapy-related toxicities. A comprehensive geriatric assessment can assist in the selection of treatment for an older adult with mCRC. While frail older patients can frequently only tolerate single agents or modified regimens, fit older adults remain candidates for a wider range of treatment options. However, since all of these treatments are associated with possible toxicities, each patient’s treatment must be personalized to the patient’s goals and wishes through a shared decision-making process.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Colorectal Cancer—Cancer Stat Facts [Internet]. 2020. https://seer.cancer.gov/statfacts/html/colorect.html. Accessed 24 Nov 2020.

  2. Wang J, Li S, Liu Y, Zhang C, Li H, Lai B. Metastatic patterns and survival outcomes in patients with stage IV colon cancer: a population-based analysis. Cancer Med [Internet]. Blackwell Publishing Ltd. 2020;9:361–73. https://doi.org/10.1002/cam4.2673

  3. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin [Internet]. American Cancer Society. 2017;67:177–93. https://pubmed.ncbi.nlm.nih.gov/28248415/. Accessed 24 Nov 2020.

  4. American Cancer Society - Cancer Statistics Center: Colorectum [Internet]. 2020. https://cancerstatisticscenter.cancer.org/?_ga=2.113690883.562831984.1606231127-1760324198.1606231127#!/. Accessed 24 Nov 2020.

  5. Singh H, Kanapuru B, Smith C, Fashoyin-Aje LA, Myers A, Kim G, et al. FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the U.S. Food and Drug Administration. J Clin Oncol. American Society of Clinical Oncology (ASCO). 2017;35:10009–10009.

  6. NCCN Guidelines: Older Adult Oncology (Version 1.2020) [Internet]. Natl Compr Cancer Netw. 2020. https://www.nccn.org/professionals/physician_gls/pdf/senior.pdf. Accessed 3 Mar 2021.

  7. Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen MLG, Extermann M, et al. International society of geriatric oncology consensus on geriatric assessment in older patients with cancer [Internet]. J Clin Oncol. American Society of Clinical Oncology; 2014. p. 2595–603. https://pubmed.ncbi.nlm.nih.gov/25071125/. Accessed 3 Mar 2021.

  8. Papamichael D, Audisio RA, Glimelius B, de Gramont A, Glynne-Jones R, Haller D, et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013 [Internet]. Ann Oncol. Oxford University Press; 2015. p. 463–76. https://pubmed.ncbi.nlm.nih.gov/25015334/. Accessed 16 Feb 2021.

  9. Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: Asco guideline for geriatric oncology. J Clin Oncol [Internet]. American Society of Clinical Oncology; 2018;36:2326–47. https://pubmed.ncbi.nlm.nih.gov/29782209/. Accessed 24 Nov 2020.

  10. Tuca A, Gallego R, Ghanem I, Gil-Raga M, Feliu J. Chemotherapy and Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. J Clin Med [Internet]. MDPI AG; 2020;9:4015. https://doi.org/10.3390/jcm9124015.

  11. Jung YH, Kim JY, Jang YN, Yoo SH, Kim GH, Lee KM, et al. Clinical characteristics and treatment propensity in elderly patients aged over 80 years with colorectal cancer. Korean J Intern Med [Internet]. Korean Association of Internal Medicine; 2018;33:1182–93. https://pubmed.ncbi.nlm.nih.gov/29166760/. Accessed 3 Mar 2021.

  12. Doat S, Thiébaut A, Samson S, Ricordeau P, Guillemot D, Mitry E. Elderly patients with colorectal cancer: treatment modalities and survival in France. National data from the ThInDiT cohort study. Eur J Cancer. Elsevier Ltd; 2014;50:1276–83.

  13. Lund CM, Vistisen KK, Dehlendorff C, Rønholt F, Johansen JS, Nielsen DL. Age-dependent differences in first-line chemotherapy in patients with metastatic colorectal cancer: the DISCO study. Acta Oncol (Madr) [Internet]. Taylor and Francis Ltd; 2018;57:1445–54. https://pubmed.ncbi.nlm.nih.gov/30375911/. Accessed 3 Mar 2021.

  14. McKibbin T, Frei CR, Greene RE, Kwan P, Simon J, Koeller JM. Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting. Oncologist [Internet]. Wiley; 2008;13:876–85. https://pubmed.ncbi.nlm.nih.gov/18695260/. Accessed 3 Mar 2021.

  15. Vijayvergia N, Li T, Wong YN, Hall MJ, Cohen SJ, Dotan E. Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer. Cancer [Internet]. John Wiley and Sons Inc.; 2016;122:3191–8. https://pubmed.ncbi.nlm.nih.gov/27379436/. Accessed 24 Nov 2020.

  16. Wildiers H, Kenis C. Comprehensive geriatric assessment (CGA) in older oncological patients: why and how? J Geriatr Oncol Elsevier. 2012;3:174–6.

    Article  Google Scholar 

  17. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer [Internet]. J Clin Oncol; 2007. p. 1824–31. https://pubmed.ncbi.nlm.nih.gov/17488980/. Accessed 25 Nov 2020.

  18. Luciani A, Ascione G, Bertuzzi C, Marussi D, Codecà C, Di Maria G, et al. Detecting disabilities in older patients with cancer: Comparison between comprehensive geriatric assessment and vulnerable elders survey-13. J Clin Oncol; 2010;28:2046–50. https://pubmed.ncbi.nlm.nih.gov/20308657/. Accessed 25 Nov 2020.

  19. Brunello A, Sandri R, Extermann M. Multidimensional geriatric evaluation for older cancer patients as a clinical and research tool [Internet]. Cancer Treat Rev; 2009. p. 487–92. https://pubmed.ncbi.nlm.nih.gov/19481353/. Accessed 25 Nov 2020.

  20. Hernandez Torres C, Hsu T. Comprehensive geriatric assessment in the older adult with cancer: a review [Internet]. Eur Urol Focus Elsevier B.V.; 2017. p. 330–9. https://pubmed.ncbi.nlm.nih.gov/29331624/. Accessed 1 Dec 2020.

  21. Seedor RS, Meeker CR, Lewis B, Handorf EA, Filchner KA, Winn JS, et al. Prospective study comparing self-administered geriatric assessment to provider’s routine clinical assessment of older patients with metastatic breast cancer treated at community oncology practices. J Clin Oncol. American Society of Clinical Oncology (ASCO); 2020;38:12029–12029.

  22. Welsh TJ, Gordon AL, Gladman JR. Comprehensive geriatric assessment—a guide for the non-specialist [Internet]. Int J Clin Pract; 2014. p. 290–3. https://pubmed.ncbi.nlm.nih.gov/24118661/. Accessed 24 Nov 2020.

  23. Caillet P, Canoui-Poitrine F, Vouriot J, Berle M, Reinald N, Krypciak S, et al. Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA Study. J Clin Oncol; 2011;29:3636–42. https://pubmed.ncbi.nlm.nih.gov/21709194/. Accessed 16 Feb 2021.

  24. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol US. 1982;5:649–55.

    Article  CAS  Google Scholar 

  25. Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky performance status scale: An examination of its reliability and validity in a research setting. Cancer [Internet]. John Wiley & Sons, Ltd; 1984;53:2002–7. https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/1097-0142%2819840501%2953%3A9%3C2002%3A%3AAID-CNCR2820530933%3E3.0.CO%3B2-W. Accessed 26 Feb 2020.

  26. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol; 2011. p. 3457–65. https://pubmed.ncbi.nlm.nih.gov/21810685/. Accessed 25 Nov 2020.

  27. Angeli E, Chouahnia K, Canoui-Poitrine F, Duchemann B, Aparicio T, Paillaud E, et al. Development, validation and clinical impact of a prediction model for 6-month mortality in older cancer patients: The GRADE. Aging (Albany NY) [Internet]. Impact Journals LLC; 2020;12:4230–46. https://pubmed.ncbi.nlm.nih.gov/32156833/. Accessed 16 Feb 2021.

  28. Raji MA, Kuo YF, Freeman JL, Goodwin JS. Effect of a dementia diagnosis on survival of older patients after a diagnosis of breast, colon, or prostate cancer: implications for cancer care. Arch Intern Med [Internet]. NIH Public Access; 2008;168:2033–40. https://doi.org/10.1001/archinte.168.18.2033.

  29. Kim KH, Lee JJ, Kim J, Zhou JM, Gomes F, Sehovic M, et al. Association of multidimensional comorbidities with survival, toxicity, and unplanned hospitalizations in older adults with metastatic colorectal cancer treated with chemotherapy. J Geriatr Oncol [Internet]. Elsevier Ltd; 2019;10:733–41. https://doi.org/10.1016/j.jgo.2019.02.003.

  30. Dotan E, Tew WP, Mohile SG, Ma H, Kim H, Sun C, et al. Associations between nutritional factors and chemotherapy toxicity in older adults with solid tumors. Cancer [Internet]. John Wiley and Sons Inc.; 2020;126:1708–16. https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.32718. Accessed 25 Nov 2020.

  31. Aaldriks AA, van der Geest LGM, Giltay EJ, le Cessie S, Portielje JEA, Tanis BC, et al. Frailty and malnutrition predictive of mortality risk in older patients with advanced colorectal cancer receiving chemotherapy. J Geriatr Oncol; 2013;4:218–26. https://pubmed.ncbi.nlm.nih.gov/24070460/. Accessed 25 Nov 2020.

  32. Martucci RB, Barbosa M V., D’Almeida CA, Rodrigues VD, Bergmann A, de Pinho NB, et al. Undernutrition as independent predictor of early mortality in elderly cancer patients. Nutrition [Internet]. Elsevier Inc.; 2017;34:65–70. https://pubmed.ncbi.nlm.nih.gov/28063514/. Accessed 25 Nov 2020.

  33. Naeim A, Aapro M, Subbarao R, Balducci L. Supportive care considerations for older adults with cancer [Internet]. J Clin Oncol American Society of Clinical Oncology; 2014. p. 2627–34. https://pubmed.ncbi.nlm.nih.gov/25071112/. Accessed 25 Nov 2020.

  34. Kua J. The prevalence of psychological and psychiatric sequelae of cancer in the elderly—how much do we know? Ann Acad Med Singap. 2005;34:250–6.

    CAS  PubMed  Google Scholar 

  35. Kalsi T, Babic-Illman G, Ross PJ, Maisey NR, Hughes S, Fields P, et al. The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people. Br J Cancer [Internet]. Nature Publishing Group; 2015;112:1435–44. https://pubmed.ncbi.nlm.nih.gov/25871332/. Accessed 24 Nov 2020.

  36. Li D, Sun C-L, Kim H, Chung V, Koczywas M, Fakih M, et al. Geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer: a randomized controlled trial. J Clin Oncol. American Society of Clinical Oncology (ASCO); 2020;38:12010–12010.

  37. Decoster L, Van Puyvelde K, Mohile S, Wedding U, Basso U, Colloca G, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations [Internet]. Ann Oncol. Oxford University Press; 2015. p. 288–300. https://pubmed.ncbi.nlm.nih.gov/24936581/. Accessed 25 Nov 2020.

  38. Aparicio T, Canouï-Poitrine F, Caillet P, François E, Cudennec T, Carola E, et al. Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG). Dig Liver Dis [Internet]. Elsevier B.V.; 2020;52:493–505. https://pubmed.ncbi.nlm.nih.gov/32029404/. Accessed 16 Feb 2021.

  39. Benson AB, Al-Hawary MM, Arain MA, Chen Y-J, Ciombor KK, Cohen S, et al. NCCN Guidelines Version 4.2020 Colon Cancer Continue NCCN Guidelines Panel Disclosures. 2020.

  40. Kemeny N. Management of liver metastases from colorectal cancer. Oncology (Williston Park). United States; 2006;20:1161–76, 1179; discussion 1179-80, 1185–6.

  41. van Tuil T, Dhaif AA, te Riele WW, van Ramshorst B, van Santvoort HC. Systematic review and meta-analysis of liver resection for colorectal metastases in elderly patients. Dig Surg [Internet]. S. Karger AG; 2019;36:111–23. https://www.karger.com/Article/FullText/487274. Accessed 24 Nov 2020.

  42. de’Angelis N, Baldini C, Brustia R, Pessaux P, Sommacale D, Laurent A, et al. Surgical and regional treatments for colorectal cancer metastases in older patients: a systematic review and meta-analysis. Nigri G, editor. PLoS One [Internet]. Public Library of Science; 2020;15:e0230914. https://dx.plos.org/10.1371/journal.pone.0230914. Accessed 24 Nov 2020.

  43. Seidensticker R, Damm R, Enge J, Seidensticker M, Mohnike K, Pech M, et al. Local ablation or radioembolization of colorectal cancer metastases: Comorbidities or older age do not affect overall survival. BMC Cancer [Internet]. BioMed Central Ltd.; 2018;18:882. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4784-9. Accessed 24 Nov 2020.

  44. Tohme S, Sukato D, Nace GW, Zajko A, Amesur N, Orons P, et al. Survival and tolerability of liver radioembolization: A comparison of elderly and younger patients with metastatic colorectal cancer. HPB [Internet]. Blackwell Publishing Ltd; 2014. p. 1110–6. https://doi.org/10.1111/hpb.12307.

  45. Kennedy AS, Ball DS, Cohen SJ, Cohn M, Coldwell D, Drooz A, et al. Safety and efficacy of radioembolization in elderly (≥ 70 years) and younger patients with unresectable liver-dominant colorectal cancer. Clin Colorectal Cancer [Internet]. Elsevier Inc.; 2016;15:141–151.e6. https://doi.org/10.1016/j.clcc.2015.09.001. Accessed 24 Nov 2020.

  46. Wild AT, Yamada Y. Treatment Options in oligometastatic disease: stereotactic body radiation therapy—focus on colorectal cancer. Visc Med [Internet]. S. Karger AG; 2017;33:54–61. https://www.karger.com/Article/FullText/454685. Accessed 24 Nov 2020.

  47. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: Mechanisms of action and clinical strategies [Internet]. Nat. Rev. Cancer. Nat Rev Cancer; 2003. p. 330–8. https://pubmed.ncbi.nlm.nih.gov/12724731/. Accessed 25 Nov 2020.

  48. Landre T, Uzzan B, Nicolas P, Aparicio T, Zelek L, Mary F, et al. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. A meta-analysis [Internet]. Int. J. Colorectal Dis. Springer Verlag; 2015. p. 1305–10. https://pubmed.ncbi.nlm.nih.gov/26099322/. Accessed 26 Feb 2021.

  49. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study. J Clin Oncol; 2006;24:394–400. https://pubmed.ncbi.nlm.nih.gov/16421419/. Accessed 25 Nov 2020.

  50. Saltz LB, Cox J V., Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med [Internet]; 2000;343:905–14. https://pubmed.ncbi.nlm.nih.gov/11006366/. Accessed 25 Nov 2020.

  51. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone. as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet [Internet]. Elsevier Limited; 2000;355:1041–7. https://pubmed.ncbi.nlm.nih.gov/10744089/. Accessed 25 Nov 2020.

  52. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol [Internet]. American Society of Clinical Oncology; 2000;18:2938–47. https://pubmed.ncbi.nlm.nih.gov/10944126/. Accessed 25 Nov 2020.

  53. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol [Internet]. J Clin Oncol; 2004;22:229–37. https://pubmed.ncbi.nlm.nih.gov/14657227/. Accessed 25 Nov 2020.

  54. Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol [Internet]. Ann Oncol; 2004;15:1330–8. https://pubmed.ncbi.nlm.nih.gov/15319237/. Accessed 25 Nov 2020.

  55. Venderbosch S, Doornebal J, Teerenstra S, Lemmens W, Punt CJA, Koopman M. Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: A retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG). Acta Oncol (Madr) [Internet]. Acta Oncol; 2012;51:831–9. https://pubmed.ncbi.nlm.nih.gov/22794910/. Accessed 3 Mar 2021.

  56. Goldberg RM, Tabah-Fisch I, Bleiberg H, De Gramont A, Tournigand C, Andre T, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol [Internet]. 2006;24:4085–91. https://pubmed.ncbi.nlm.nih.gov/16943526/. Accessed 25 Nov 2020.

  57. Aparicio T, Gargot D, Teillet L, Maillard E, Genet D, Cretin J, et al. Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients. Eur J Cancer [Internet]. Elsevier Ltd; 2017;74:98–108. https://pubmed.ncbi.nlm.nih.gov/27825697/. Accessed 25 Nov 2020.

  58. Aparicio T, Jouve JL, Teillet L, Gargot D, Subtil F, Le Brun-Ly V, et al. Geriatric factors predict chemotherapy feasibility: Ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol; 2013;31:1464–70. https://pubmed.ncbi.nlm.nih.gov/23460711/. Accessed 2 Mar 2021.

  59. Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet [Internet]. Lancet; 2011;377:1749–59. https://pubmed.ncbi.nlm.nih.gov/21570111/. Accessed 25 Nov 2020.

  60. Souglakos J, Pallis A, Kakolyris S, Mavroudis D, Androulakis N, Kouroussis C, et al. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. Oncology; 2005;69:384–90. https://pubmed.ncbi.nlm.nih.gov/16319509/. Accessed 25 Nov 2020.

  61. Folprecht G, Seymour MT, Saltz L, Douillard JY, Hecker H, Stephens RJ, et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol; 2008;26:1443–51. https://pubmed.ncbi.nlm.nih.gov/18349394/. Accessed 25 Nov 2020.

  62. Aparicio T, Lavau-Denes S, Phelip JM, Maillard E, Jouve JL, Gargot D, et al. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). Ann Oncol [Internet]. Oxford University Press; 2016;27:121–7. https://pubmed.ncbi.nlm.nih.gov/26487578/. Accessed 25 Nov 2020.

  63. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol [Internet]. Lippincott Williams and Wilkins; 2001;19:2282–92. https://pubmed.ncbi.nlm.nih.gov/11304782/. Accessed 25 Nov 2020.

  64. Van Cutsen E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol [Internet]. Lippincott Williams and Wilkins; 2001;19:4097–106. https://pubmed.ncbi.nlm.nih.gov/11689577/. Accessed 25 Nov 2020.

  65. Twelves C, Gollins S, Grieve R, Samuel L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol; 2006;17:239–45. https://pubmed.ncbi.nlm.nih.gov/16344278/. Accessed 25 Nov 2020.

  66. Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol; 2008;26:2006–12. https://pubmed.ncbi.nlm.nih.gov/18421053/. Accessed 25 Nov 2020.

  67. Feliu J, Salud A, Escudero P, Lopez-Gómez L, Bolaños M, Galán A, et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer [Internet]. Nature Publishing Group; 2006;94:969–75. https://doi.org/10.1038/sj.bjc.6603047.

  68. Rosati G, Cordio S, Bordonaro R, Caputo G, Novello G, Reggiardo G, et al. Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: Results of a randomized phase II study. Ann Oncol; 2009;21:781–6. https://pubmed.ncbi.nlm.nih.gov/19713248/. Accessed 25 Nov 2020.

  69. Vincent MD, Breadner D, Cripps MC, Jonker DJ, Klimo P, Biagi JJ, et al. Phase I/II trial of dose-reduced capecitabine in elderly patients with advanced colorectal cancer. Curr Oncol [Internet]. Multimed Inc.; 2017;24:e261–8. https://doi.org/10.3747/co.24.3516.

  70. Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, Van hazel GA, et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: A subgroup analysis from the AGITG MAX trial: An international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. Ann Oncol [Internet]. Oxford University Press; 2012;23:1531–6. https://pubmed.ncbi.nlm.nih.gov/22039086/. Accessed 2 Mar 2021.

  71. Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: Pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol [Internet]. American Society of Clinical Oncology; 2009;27:199–205. http://ascopubs.org/doi/10.1200/JCO.2008.17.7931. Accessed 25 Nov 2020.

  72. Koch C, Schwing AM, Herrmann E, Borner M, Diaz-Rubio E, Dotan E, et al. Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: An individual patient data based meta-analysis. Oncotarget [Internet]. Impact Journals LLC; 2018;9:10272–83. www.impactjournals.com/oncotarget/. Accessed 25 Nov 2020.

  73. Landre T, Maillard E, Taleb C, Ghebriou D, Guetz G Des, Zelek L, et al. Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients. Int J Colorectal Dis [Internet]. Springer Verlag; 2018;33:1125–30. https://pubmed.ncbi.nlm.nih.gov/29680896/. Accessed 2 Mar 2021.

  74. Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): An open-label, randomised phase 3 trial. Lancet Oncol [Internet]. Elsevier; 2013;14:1077–85. www.thelancet.com/oncology. Accessed 25 Nov 2020.

  75. Aparicio T, Bouché O, Taieb J, Maillard E, Kirscher S, Etienne PL, et al. Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results. Ann Oncol [Internet]. Oxford University Press; 2018;29:133–8. https://pubmed.ncbi.nlm.nih.gov/29045659/. Accessed 25 Nov 2020.

  76. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, et al. Clinical Outcomes associated with bevacizumab‐containing treatment of metastatic colorectal cancer: the BRiTE Observational Cohort Study. Oncologist [Internet]. Wiley; 2009;14:862–70. https://pubmed.ncbi.nlm.nih.gov/19726453/. Accessed 26 Nov 2020.

  77. Cassidy J, Saltz LB, Giantonio BJ, Kabbinavar FF, Hurwitz HI, Rohr UP. Effect of bevacizumab in older patients with metastatic colorectal cancer: Pooled analysis of four randomized studies. J Cancer Res Clin Oncol; 2010;136:737–43. https://pubmed.ncbi.nlm.nih.gov/19904559/. Accessed 25 Nov 2020.

  78. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, Dibartolomeo M, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol; 2009 [cited 2020 Nov 26];20:1842–7. https://pubmed.ncbi.nlm.nih.gov/19406901/. Accessed 26 Nov 2020.

  79. Kozloff MF, Berlin J, Flynn PJ, Kabbinavar F, Ashby M, Dong W, et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: Results from the BRiTE observational cohort study. Oncology [Internet]. Oncology; 2010;78:329–39. https://pubmed.ncbi.nlm.nih.gov/20733336/. Accessed 26 Nov 2020.

  80. Tsai HT, Marshall JL, Weiss SR, Huang CY, Warren JL, Freedman AN, et al. Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study. Ann Oncol; 2013;24:1574–9. https://pubmed.ncbi.nlm.nih.gov/23429865/. Accessed 26 Nov 2020.

  81. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol; 2012;30:3499–506. https://pubmed.ncbi.nlm.nih.gov/22949147/. Accessed 26 Nov 2020.

  82. Troiani T, Martinelli E, Orditura M, De Vita F, Ciardiello F, Morgillo F. Beyond bevacizumab: New anti-VEGF strategies in colorectal cancer [Internet]. Expert Opin Investig Drugs; 2012. p. 949–59. https://pubmed.ncbi.nlm.nih.gov/22612461/. Accessed 26 Nov 2020.

  83. Ruff P, Van Cutsem E, Lakomy R, Prausova J, van Hazel GA, Moiseyenko VM, et al. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: an age-based analysis from the randomized placebo-controlled phase III VELOUR trial. J Geriatr Oncol [Internet]. Elsevier Ltd; 2018;9:32–9. https://pubmed.ncbi.nlm.nih.gov/28807738/. Accessed 26 Nov 2020.

  84. Martínez-Lago N, Carmona Campos M, Gonzalez Villarroel P, Salgado Fernandez M, De la Cámara Gómez J, Romero Reinoso C, et al. Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen. Ann Oncol [Internet]. Elsevier BV; 2019;30:iv42–3. http://www.annalsofoncology.org/article/S0923753419306763/fulltext. Accessed 26 Nov 2020.

  85. Obermannová R, Van Cutsem E, Yoshino T, Bodoky G, Prausová J, Garcia-Carbonero R, et al. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. Ann Oncol [Internet]. Oxford University Press; 2016;27:2082–9. https://pubmed.ncbi.nlm.nih.gov/27573561/. Accessed 26 Nov 2020.

  86. Muro K, Cho JY, Bodoky G, Goswami C, Chao Y, dos Santos LV, et al. Efficacy and safety of ramucirumab (RAM) for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma across age subgroups in two global phase 3 trials. J Clin Oncol. American Society of Clinical Oncology (ASCO); 2017;35:3–3.

  87. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol [Internet]. Oxford University Press; 2014;25:1346–55. https://pubmed.ncbi.nlm.nih.gov/24718886/. Accessed 26 Nov 2020.

  88. Bouchahda M, Macarulla T, Spano JP, Bachet JB, Lledo G, Andre T, et al. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer [Internet]. Crit Rev Oncol Hematol; 2008. p. 255–62. https://pubmed.ncbi.nlm.nih.gov/18400508/. Accessed 26 Nov 2020.

  89. Sastre J, Grávalos C, Rivera F, Massuti B, Valladares‐Ayerbes M, Marcuello E, et al. First‐Line Cetuximab Plus Capecitabine in Elderly Patients with Advanced Colorectal Cancer: Clinical Outcome and Subgroup Analysis According to KRAS Status from a Spanish TTD Group Study . Oncologist [Internet]. Wiley; 2012;17:339–45. https://doi.org/10.1634/theoncologist.2011-0406.

  90. Dotan E, Devarajan K, D’Silva AJ, Beck A, Kloth DD, Cohen SJ, et al. Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer. Clin Colorectal Cancer [Internet]. Elsevier Inc.; 2014;13:192–8. https://pubmed.ncbi.nlm.nih.gov/25074246/. Accessed 26 Nov 2020.

  91. Lonardi S, Schirripa M, Buggin F, Antonuzzo L, Merelli B, Boscolo G, et al. First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: the PANDA study. J Clin Oncol. American Society of Clinical Oncology (ASCO); 2020;38:4002–4002.

  92. Battaglin F, Schirripa M, Buggin F, Pietrantonio F, Morano F, Boscolo G, et al. The PANDA study: A randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. BMC Cancer [Internet]. BioMed Central Ltd.; 2018;18. https://pubmed.ncbi.nlm.nih.gov/29370781/. Accessed 26 Nov 2020.

  93. Aparicio T, Schischmanoff O, Poupardin C, Soufir N, Angelakov C, Barrat C, et al. Deficient mismatch repair phenotype is a prognostic factor for colorectal cancer in elderly patients. Dig Liver Dis [Internet]. Dig Liver Dis; 2013;45:245–50. https://pubmed.ncbi.nlm.nih.gov/23102497/. Accessed 26 Nov 2020.

  94. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med [Internet]; 2015;372:2509–20. https://pubmed.ncbi.nlm.nih.gov/26028255/. Accessed 26 Nov 2020.

  95. Andre T, Shiu K-K, Kim TW, Jensen BV, Jensen LH, Punt CJA, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: the phase 3 KEYNOTE-177 Study. J Clin Oncol. American Society of Clinical Oncology (ASCO); 2020;38:LBA4–LBA4.

  96. Sakakida T, Ishikawa T, Uchino J, Tabuchi Y, Komori S, Asai J, et al. Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies. Oncol Lett [Internet]. Spandidos Publications; 2020;20. https://pubmed.ncbi.nlm.nih.gov/32774487/. Accessed 26 Nov 2020.

  97. Nishijima TF, Shachar SS, Nyrop KA, Muss HB. Safety and Tolerability of PD‐1/PD‐L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta‐Analysis. Oncologist [Internet]. Wiley; 2017;22:470–9. https://pubmed.ncbi.nlm.nih.gov/28275115/. Accessed 26 Nov 2020.

  98. van Holstein Y, Kapiteijn E, Bastiaannet E, van den Bos F, Portielje J, de Glas NA. Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer [Internet]. Drugs and Aging. Springer International Publishing; 2019. p. 927–38. https://pubmed.ncbi.nlm.nih.gov/31317421/. Accessed 26 Nov 2020.

  99. Tol J, Nagtegaal ID, Punt CJA. BRAF Mutation in Metastatic Colorectal Cancer . N Engl J Med [Internet]. New England Journal of Medicine (NEJM/MMS); 2009;361:98–9. https://pubmed.ncbi.nlm.nih.gov/19571295/. Accessed 26 Nov 2020.

  100. Ducreux M, Chamseddine A, Laurent-Puig P, Smolenschi C, Hollebecque A, Dartigues P, et al. Molecular targeted therapy of BRAF-mutant colorectal cancer [Internet]. Ther Adv Med Oncol. SAGE Publications Inc.; 2019. https://doi.org/10.1177/1758835919856494.

  101. Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol [Internet]. Lancet Publishing Group; 2015;16:1306–15. https://pubmed.ncbi.nlm.nih.gov/26338525/. Accessed 26 Nov 2020.

  102. Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer . N Engl J Med [Internet]. Massachusetts Medical Society; 2019;381:1632–43. https://www.nejm.org/doi/10.1056/NEJMoa1908075. Accessed 25 Nov 2020.

  103. Kopetz S, Grothey A, Van Cutsem E, Yaeger R, Wasan HS, Yoshino T, et al. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). J Clin Oncol. American Society of Clinical Oncology (ASCO); 2020;38:4001–4001.

  104. Figer A, Perez-Staub N, Carola E, Tournigand C, Lledo G, Flesch M, et al. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: An exploratory cohort of the OPTIMOX1 study. Cancer [Internet]. Cancer; 2007;110:2666–71. https://pubmed.ncbi.nlm.nih.gov/17963264/. Accessed 25 Nov 2020.

  105. André T, Tournigand C, Mineur L, Fellague-Chebra R, Flesch M, Mabro M, et al. Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: A GERCOR study. Ann Oncol [Internet]. Ann Oncol; 2007;18:77–81. https://pubmed.ncbi.nlm.nih.gov/17030548/. Accessed 26 Nov 2020.

  106. Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, André T, Bennamoun M, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study. J Clin Oncol [Internet]. J Clin Oncol; 2009;27:5727–33. https://pubmed.ncbi.nlm.nih.gov/19786657/. Accessed 26 Nov 2020.

  107. Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): A randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol [Internet]. Lancet Publishing Group; 2015 ;16:1355–69. https://pubmed.ncbi.nlm.nih.gov/26361971/. Accessed 2 Mar 2021.

  108. Simkens LHJ, Van Tinteren H, May A, Ten Tije AJ, Creemers GJM, Loosveld OJL, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): A phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet [Internet]. Lancet Publishing Group; 2015;385:1843–52. https://pubmed.ncbi.nlm.nih.gov/25862517/. Accessed 2 Mar 2021.

  109. Pietrantonio F, Morano F, Corallo S, Lonardi S, Cremolini C, Rimassa L, et al. First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. J Clin Oncol. American Society of Clinical Oncology (ASCO); 2018;36:3505–3505.

  110. Grothey A, Prager G, Yoshino T. The mechanism of action of regorafenib in colorectal cancer: a guide for the community physician. Clin Adv Hematol Oncol. United States; 2019;17 Suppl 1:1–19.

  111. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet [Internet]. Lancet Publishing Group; 2013;381:303–12. http://www.thelancet.com/article/S014067361261900X/fulltext. Accessed 26 Nov 2020.

  112. van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, et al. Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial. J Clin Oncol. American Society of Clinical Oncology (ASCO); 2013;31:3636–3636.

  113. Carrato A, Benavides M, Massutí B, Ferreiro-Monteagudo R, García Alfonso P, Falcó E, et al. First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: A pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). BMC Cancer [Internet]. BioMed Central Ltd.; 2019;19. https://pubmed.ncbi.nlm.nih.gov/31159765/. Accessed 26 Nov 2020.

  114. Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol [Internet]. Lancet Publishing Group; 2019;20:1070–82. https://pubmed.ncbi.nlm.nih.gov/31262657/. Accessed 26 Nov 2020.

  115. Petrioli R, Chirra M, Messuti L, Fiaschi AI, Savelli V, Martellucci I, et al. Efficacy and safety of regorafenib with 2/1 schedule for patients ≥ 75 years with metastatic colorectal cancer (mCRC) After failure of 2 lines of chemotherapy. Clin Colorectal Cancer [Internet]. Elsevier Inc.; 2018;17:307–12. https://pubmed.ncbi.nlm.nih.gov/29548772/. Accessed 3 Mar 2021.

  116. Aparicio T, Darut-Jouve A, Khemissa Akouz F, Montérymard C, Artru P, Cany L, et al. Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 – REGOLD. J Geriatr Oncol [Internet]. Elsevier Ltd; 2020 ;11:1255–62. https://pubmed.ncbi.nlm.nih.gov/32334940/. Accessed 3 Mar 2021.

  117. Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med [Internet]. Massachusetts Medical Society; 2015;372:1909–19. https://www.nejm.org/doi/full/10.1056/NEJMoa1414325. Accessed 26 Nov 2020.

  118. Makiyama A, Oki E, Miyamoto Y, Kotaka M, Kawanaka H, Miwa K, et al. Bevacizumab plus trifluridine/tipiracil in elderly patients with previously untreated metastatic colorectal cancer (KSCC 1602): a single-arm, phase II study. Ann Oncol [Internet]. Elsevier BV; 2019;30:v234–5. http://www.annalsofoncology.org/article/S0923753419588408/fulltext. Accessed 26 Nov 2020.

  119. Van Cutsem E, Danielewicz I, Saunders MP, Pfeiffer P, Argilés G, Borg C, et al. Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study. Ann Oncol [Internet]. Elsevier Ltd; 2020;31:1160–8. https://pubmed.ncbi.nlm.nih.gov/32497736/. Accessed 26 Nov 2020.

  120. Mariano C, Jamal R, Bains P, Hejazi S, Chao L, Wan J, et al. Utility of a chemotherapy toxicity prediction tool for older patients in a community setting. Curr Oncol [Internet]. Multimed Inc.; 2019;26:234–9. https://doi.org/10.3747/co.26.4869.

  121. Hurria A, Gupta S, Zauderer M, Zuckerman EL, Cohen HJ, Muss H, et al. Developing a cancer-specific geriatric assessment: A feasibility study [Internet]. Cancer. Cancer; 2005. p. 1998–2005. https://pubmed.ncbi.nlm.nih.gov/16206252/. Accessed 26 Nov 2020.

  122. Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, Defelice J, et al. Predicting the risk of chemotherapy toxicity in older patients: The chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer [Internet]. Cancer; 2012;118:3377–86. https://pubmed.ncbi.nlm.nih.gov/22072065/. Accessed 26 Nov 2020.

  123. Retornaz F, Guillem O, Rousseau F, Morvan F, Rinaldi Y, Nahon S, et al. Predicting chemotherapy toxicity and death in older adults with colon cancer: results of MOST study. Oncologist [Internet]. Wiley; 2020;25. https://pubmed.ncbi.nlm.nih.gov/31387952/. Accessed 16 Feb 2021.

  124. Saif MW. An adverse interaction between warfarin and fluoropyrimidines revisited. [Internet]. Clin Colorectal Cancer; 2005. p. 175–80. https://pubmed.ncbi.nlm.nih.gov/16197620/. Accessed 26 Nov 2020.

  125. Whitman AM, DeGregory KA, Morris AL, Ramsdale EE. A comprehensive look at polypharmacy and medication screening tools for the older cancer patient. Oncologist [Internet]. Wiley; 2016;21:723–30. https://doi.org/10.1634/theoncologist.2015-0492.

  126. Hersh LR, Beldowski K, Hajjar ER. Polypharmacy in the Geriatric Oncology Population [Internet]. Curr Oncol Rep. Current Medicine Group LLC 1; 2017. https://pubmed.ncbi.nlm.nih.gov/28942563/. Accessed 26 Nov 2020.

  127. Raphael MJ, Fischer HD, Fung K, Austin PC, Anderson GM, Booth CM, et al. Neurotoxicity outcomes in a population-based cohort of elderly patients treated with adjuvant oxaliplatin for colorectal cancer. Clin Colorectal Cancer [Internet]. Elsevier Inc.; 2017;16:397-404.e1. https://pubmed.ncbi.nlm.nih.gov/28434884/. Accessed 26 Nov 2020.

Download references

Author information

Author notes

  1. Erika Correa and Timothy Lindsay contributed equally to the manuscript.

Authors and Affiliations

  1. Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA

    Erika Correa, Timothy Lindsay & Efrat Dotan

Authors
  1. Erika Correa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy Lindsay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Efrat Dotan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Efrat Dotan.

Ethics declarations

Funding

Supported by a Cancer Center Support Grant 3 P30 CA006927. No external funding was used in the preparation of this manuscript.

Conflict of interest

Erika Correa, MD, MS and Timothy Lindsay, MD declare that they have no conflicts of interest that might be relevant to the contents of this manuscript. Efrat Dotan, MD has received research grants paid to her institution from the following: Lilly, Pfizer, Incyte, Boston Biomedical, Medimmune, and AstraZeneca. Efrat Dotan, MD has received honoraria from QED, Basilea, and Boston Biomedical.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Code availability

Not applicable.

Authors' contributions

All authors contributed equally to the completion of this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Correa, E., Lindsay, T. & Dotan, E. Management of Metastatic Colorectal Carcinoma in Older Adults: Balancing Risks and Benefits of Novel Therapies. Drugs Aging 38, 639–654 (2021). https://doi.org/10.1007/s40266-021-00869-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-021-00869-z

Search

Navigation